Trial Profile
A randomized, controlled, multicentre trial regarding the safety and feasibility of treatment with empagliflozin compared with NPH insulin treatment in patients with newly onset diabetes following initiation of glucocorticoid treatment.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 31 Jan 2022
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Insulin
- Indications Diabetes mellitus
- Focus Therapeutic Use
- Acronyms EANITIATE
- 28 Jan 2022 Status changed from recruiting to discontinued.
- 10 Dec 2018 New trial record